ibipinabant   Click here for help

GtoPdb Ligand ID: 9234

Synonyms: BMS-646256 | SLV319 [1]
Compound class: Synthetic organic
Comment: Ibipinabant is a selective cannabinoid CB1 receptor antagonist [1], investigated for its clinical potential as an anti-obesity drug.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 82.51
Molecular weight 486.07
XLogP 6.14
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN=C(N1N=C(C(C1)c1ccccc1)c1ccc(cc1)Cl)NS(=O)(=O)c1ccc(cc1)Cl
Isomeric SMILES CN=C(N1N=C([C@H](C1)c1ccccc1)c1ccc(cc1)Cl)NS(=O)(=O)c1ccc(cc1)Cl
InChI InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28)/t21-/m1/s1
InChI Key AXJQVVLKUYCICH-OAQYLSRUSA-N
No information available.
Summary of Clinical Use Click here for help
A phase 2/3 clinical trial designed to evaluate ibipinabant as an anti-obesity drug in obese and overweight patients with type 2 diabetes (NCT00541567) was withdrawn before enrolling any participants. Phase 2 trial NCT00388609 in obese patients was terminated early.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00388609 Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects Phase 2 Interventional Bristol-Myers Squibb
NCT00541567 BMS-646256 in Obese and Overweight Type 2 Diabetics Phase 2/Phase 3 Interventional Solvay Pharmaceuticals